We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , AstraZeneca PLC (AZN - Free Report) and Arista Networks, Inc. (ANET - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Chevron, AstraZeneca and Arista Networks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp., AstraZeneca PLC and Arista Networks, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Chevron’s shares have underperformed the Zacks Oil and Gas – Integrated – International industry over the past two years (-11.6% vs. +0.4%). The Zacks analyst believes that the energy major is highly exposed to the perils of oil price fluctuations.
Moreover, its planned acquisition of Hess Corporation faces regulatory scrutiny and legal challenges. Chevron has been a laggard compared to its European peers to jump onto the clean energy bandwagon.
However, Chevron has improved its cash from operations, allowing management to raise dividends regularly.
AstraZeneca’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last six months (-12.5% vs. -5.3%). The Zacks analyst believes that AstraZeneca’s diabetes franchise faces stiff competition, while pricing pressure hurts sales in the respiratory unit.
Yet, alongside investments in emerging markets, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving the company’s revenues. AstraZeneca’s pipeline is strong, with important pipeline data readouts lined up.
Shares of Arista Networks have outperformed the Zacks Communication - Components industry over the past year (+83.1% vs. +75.7%). Per the Zacks analyst, the company is benefiting from solid demand, driven by strong momentum in AI workloads, cloud networking and data center. Innovation in areas such as deep packet buffers, embedded optics and reversible cooling augurs well for its long-term growth.
However, Arista is up against some of the toughest competitors in cloud networking solutions. Customer concentration risk is also a concern.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks
For Immediate Release
Chicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , AstraZeneca PLC (AZN - Free Report) and Arista Networks, Inc. (ANET - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Chevron, AstraZeneca and Arista Networks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp., AstraZeneca PLC and Arista Networks, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Chevron’s shares have underperformed the Zacks Oil and Gas – Integrated – International industry over the past two years (-11.6% vs. +0.4%). The Zacks analyst believes that the energy major is highly exposed to the perils of oil price fluctuations.
Moreover, its planned acquisition of Hess Corporation faces regulatory scrutiny and legal challenges. Chevron has been a laggard compared to its European peers to jump onto the clean energy bandwagon.
However, Chevron has improved its cash from operations, allowing management to raise dividends regularly.
(You can read the full research report on Chevron here >>>)
AstraZeneca’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last six months (-12.5% vs. -5.3%). The Zacks analyst believes that AstraZeneca’s diabetes franchise faces stiff competition, while pricing pressure hurts sales in the respiratory unit.
Yet, alongside investments in emerging markets, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving the company’s revenues. AstraZeneca’s pipeline is strong, with important pipeline data readouts lined up.
(You can read the full research report on AstraZeneca here >>>)
Shares of Arista Networks have outperformed the Zacks Communication - Components industry over the past year (+83.1% vs. +75.7%). Per the Zacks analyst, the company is benefiting from solid demand, driven by strong momentum in AI workloads, cloud networking and data center. Innovation in areas such as deep packet buffers, embedded optics and reversible cooling augurs well for its long-term growth.
However, Arista is up against some of the toughest competitors in cloud networking solutions. Customer concentration risk is also a concern.
(You can read the full research report on Arista Networks here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.